Publication: Antibacterial potential of a novel peptide from the consensus sequence of dermaseptin related peptides secreted by agalychnis annae
9
Issued Date
2021-01-01
Resource Type
ISSN
18734316
13892010
13892010
Other identifier(s)
2-s2.0-85112119673
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Current Pharmaceutical Biotechnology. Vol.22, No.9 (2021), 1216-1227
Suggested Citation
Ya’U Sabo Ajingi, Auwal Muhammad, Pongsak Khunrae, Triwit Rattanarojpong, Kovit Pattanapanyasat, Thana Sutthibutpong, Nujarin Jongruja Antibacterial potential of a novel peptide from the consensus sequence of dermaseptin related peptides secreted by agalychnis annae. Current Pharmaceutical Biotechnology. Vol.22, No.9 (2021), 1216-1227. doi:10.2174/1389201021666201020161428 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/76350
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Antibacterial potential of a novel peptide from the consensus sequence of dermaseptin related peptides secreted by agalychnis annae
Abstract
Background: The consistently increasing reports of bacterial resistance and the reemergence of bacterial epidemics have inspired the health and scientific community to discover new molecules with antibacterial potential continuously. Frog-skin secretions constitute bioactive compounds essential for finding new biopharmaceuticals. The exact antibacterial characterization of dermaseptin related peptides derived from Agalychnis annae, is limited. The resemblance in their conserved and functionally linked genomes indicates an unprecedented opportunity to obtain novel bioactive compounds. Objective: In this study, we derived a novel peptide sequence and determined its antibacterial potentials. Methods: Consensus sequence strategy was used to design the novel and active antibacterial peptide named 'AGAAN' from skin secretions of Agalychnis annae. The in-vitro activities of the novel peptide against some bacterial strains were investigated. Time kill studies, DNA retardation, cytotoxicity, betagalactosidase, and molecular computational studies were conducted. Results: AGAAN inhibited P. aeruginosa, E. faecalis, and S. typhimurium at 20 µM concentration. E. coli and S. aureus were inhibited at 25 µM, and lastly, B. subtilis at 50 µM. Kinetics of inactivation against exponential and stationary growing bacteria was found to be rapid within 1-5 hours of peptide exposure, depending on time and concentration. The peptide displayed weak hemolytic activity between 0.01%-7.31% at the antibacterial concentrations. AGAAN efficiently induced bacterial membrane damage with subsequent cell lysis. The peptide's DNA binding shows that it also targets intracellular DNA by retarding its movement. Our in-silico molecular docking analysis displayed a strong affinity to the bacterial cytoplasmic membrane. Conclusion: AGAAN exhibits potential antibacterial properties that could be used to combat bacterial resistance.